Santen Pharmaceutical Co., Ltd.

Hidehito Matsuoka

Shiro Mita

Kazuo Nishimura

Masaaki Murai

Hiroyuki Aono

Hisayuki Seike

An object of the present invention is to find new pharmacological actions of urea compounds having structure represented by the general formula [1]. The urea compounds having the structure represented by the general formula [1] have excellent angiogenesis inhibitory actions. [wherein 'A' is &#x2014;(NR)&#x2014;, &#x2014;(CRR)&#x2014; or &#x2014;O&#x2014;, 'B' is alkylene or alkenylene, R, R, R, Rand Rare hydrogen, alkyl, alkenyl, adamantylalkyl or the like, Ris aryl or an unsaturated heterocycle, and X is oxygen or sulfur].

Angiogenesis inhibitor

A method for inhibiting angiogenesis comprising administering to a patient (mammal, such as a human) in need thereof, a pharmaceutically effective amount of an angiogenesis inhibitor containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, either alone or in combination with a pharmaceutically acceptable carrier. The method of treatment may be used to treat diseases in which the angiogenesis participates, particularly retinal diseases such as diabetic retinopathy, macular degeneration, retinal vein occlusion and retinal artery occlusion, neovascular glaucoma and tumors such as hemangioma.

Growing community of inventors

Ikoma, Japan

Hidehito Matsuoka